Veradermics Future Growth

Future criteria checks 0/6

Veradermics is forecast to grow earnings and revenue by 50.4% and 60% per annum respectively. EPS is expected to grow by 104.3% per annum. Return on equity is forecast to be 12.2% in 3 years.

Key information

50.4%

Earnings growth rate

104.29%

EPS growth rate

Pharmaceuticals earnings growth	14.4%
Revenue growth rate	60.0%
Future return on equity	12.20%
Analyst coverage	Low
Last updated	13 May 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Apr 28

Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline Thesis

Summary Veradermics delivered robust Phase 2/3 data for VDPHL01, showing 30–33 hairs/cm² regrowth vs. 7/cm² placebo and placebo-like safety. MANE’s late-stage, oral, extended-release minoxidil targets a large, underserved cash-pay hair loss market, with rapid onset and high patient satisfaction. The current $3.7B market cap reflects high expectations for VDPHL01’s regulatory approval and commercialization as a first-in-class oral therapy. A strong cash position post-offering supports Phase 3 completion; execution on VDPHL01 is central to valuation and future stock momentum. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NYSE:MANE - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	168	-116	-105	-104	3
12/31/2027	17	-101	-103	-102	3
12/31/2026	N/A	-119	-107	-104	4
12/31/2025	N/A	-83	-72	-72	N/A
9/30/2025	N/A	-62	-52	-52	N/A
12/31/2024	N/A	-27	-24	-24	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MANE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MANE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MANE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MANE is forecast to have no revenue next year.

High Growth Revenue: MANE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MANE's Return on Equity is forecast to be low in 3 years time (12.2%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/13 11:26
End of Day Share Price	2026/05/13 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Veradermics, Incorporated is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Prakhar Agrawal	Cantor Fitzgerald & Co.
Geoffrey Meacham	Citigroup Inc
Roger Song	Jefferies LLC